Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.37 |
| ▸ | ESR1 | P03372 | 5/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.35 |
| ▸ | PDE2A | O00408 | 2/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31269323 | 0.96 | HRH4 (0.40) | DRD2ESR1ESR2HRH4KDM4E | |
| SCHEMBL30983472 | 0.94 | PDE2A (0.37) | DRD2ESR1ESR2HRH4PDE2A | |
| SCHEMBL31269378 | 0.91 | PIK3CD (0.34) | DRD2HRH4KDM4EPIK3CD | |
| SCHEMBL31269029 | 0.90 | PDK2 (0.37) | DRD2ESR1ESR2HRH4KDM4E | |
| SCHEMBL31269018 | 0.88 | PIK3CD (0.33) | KDM4EPIK3CD | |
| SCHEMBL31268820 | 0.88 | PIK3CD (0.33) | TLR7PIK3CD | |
| SCHEMBL30983381 | 0.88 | PDE2A (0.37) | DRD2ESR1ESR2HRH4PDE2A | |
| SCHEMBL31269206 | 0.88 | PIK3CD (0.33) | HRH4PIK3CD | |
| SCHEMBL31268797 | 0.88 | TLR7 (0.33) | HRH4TLR7PIK3CD | |
| SCHEMBL31268781 | 0.87 | HRH4 (0.34) | HRH4PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4689155-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | Astrazeneca AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| WO-2024201368-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | ASTRAZENECA AB (SE) | 2024-10-03 | — | — | WO | disclosed |